Related Experiment Video
Updated: Jul 28, 2026

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
Published on: May 5, 2021
Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i
Anna Simanenkova1,2, Oksana Fuks1, Natalya Timkina1,2
1Institution of Endocrinology, Almazov National Medical Research Centre, 197341 Saint-Petersburg, Russia.
Background:
Acute and chronic brain damage in type 2 diabetes mellitus (DM) determines the need to investigate the neuroprotective potential of glucose-lowering drugs. The purpose was to directly compare the neuroprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) with different duration of action and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in type 2 diabetic rats with and without stroke.
Methods:
DM was modelled using high-fat diet and nicotinamide+streptozotocin protocol. The following groups (n = 15 each) were formed: DM without treatment, treatment with liraglutide, dulaglutide, canagliflozin as well as control group without DM and treatment. After 8 weeks, 10 rats from each group underwent middle cerebral artery occlusion. In the reperfusion period neurological deficit, neuroglial damage markers and brain necrosis were evaluated. Brain slices from the remaining 5 animals in each group were histologically examined for microglial activation and neuronal damage.
Results:
Brain damage was similar in "DM" and "Control" (17.53 [14.23; 26.58] and 15.87 [13.40; 22.68] % of total brain volume, respectively). All study drugs diminished damage volume comparing with "DM" and "Control" whereas the necrosis volume in "DM+Liraglutide" was smaller than in "DM+Canagliflozin" and did not significantly differ from "DM+Dulaglutide" (2.9 [1.83; 4.71], 6.17 [3.88; 8.88] and 4.57 [3.27; 7.90] %). The neurological deficit was more prominent in "DM" than in "Control", while all the drugs demonstrated similar positive effect. Neurofilament light chains (NLC) did not differ between "DM" and "Control". Dulaglutide and canagliflozin caused a marked decrease in NLC. Protein S100BB level was similar in "DM" and "Control". Liraglutide caused the largest S100BB decrease, while canagliflozin did not influence it. In chronic brain ischaemia, all drugs increased the number of normal neurons, but GLP-1RAs had a more pronounced effect. DM was accompanied by increased number of activated microglial cells in Cornu Ammonis (CA)1 hippocampal region. Both GLP-1RAs reduced the number of Iba-1-positive cells, with dulaglutide being more effective than liraglutide, whereas canagliflozin did not affect this parameter.
Conclusions:
GLP-1RAs and SGLT-2i have neuroprotective properties against acute and chronic brain damage in diabetic rats, although the infarct-limiting effect of GLP-1RAs may be more pronounced. GLP-1RAs and SGLT-2i exert their protective effects by directly influencing neuronal survival, whereas GLP-1RAs also affect microglia.
Insights
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) show neuroprotective effects in diabetic rats. GLP-1RAs demonstrated a more pronounced effect on reducing infarct volume and microglial activation.
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (DM) is associated with acute and chronic brain damage.
- Investigating neuroprotective agents is crucial for managing diabetic complications.
- Glucose-lowering drugs, specifically GLP-1RAs and SGLT-2i, are candidates for neuroprotection.
Purpose of the Study:
- To directly compare the neuroprotective effects of GLP-1RAs (liraglutide, dulaglutide) and SGLT-2i (canagliflozin).
- To evaluate these effects in type 2 diabetic rats with and without induced stroke.
- To assess both acute and chronic brain damage models.
Main Methods:
- Type 2 diabetes mellitus was induced in rats using a high-fat diet and nicotinamide+streptozotocin.
- Animals were treated with liraglutide, dulaglutide, or canagliflozin for 8 weeks.
- Middle cerebral artery occlusion was performed to model stroke; neurological deficit, neuroglial markers, and brain necrosis were assessed.
Main Results:
- All tested drugs reduced brain damage volume compared to untreated diabetic rats.
- GLP-1RAs (liraglutide, dulaglutide) showed a more pronounced reduction in infarct volume than SGLT-2i (canagliflozin).
- GLP-1RAs, particularly dulaglutide, were more effective in reducing microglial activation and neurofilament light chains.
Conclusions:
- Both GLP-1RAs and SGLT-2i possess significant neuroprotective properties against acute and chronic brain damage in type 2 diabetes.
- GLP-1RAs appear to offer a more pronounced infarct-limiting effect.
- Neuroprotection is achieved through direct neuronal survival influence, with GLP-1RAs also modulating microglial activity.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

